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’INTRODUCTION
Microsomal prostaglandin E2 synthase-1 (mPGES-1) is a key
enzyme in the prostaglandin (PG)E2 biosynthetic pathway with-
inthearachidonicacidcascade.Inthiscascade,phospholipaseA2
(PLA2) releases arachidonic acid from membrane phospholipids
as a ﬁrst step. Then, cyclooxygenase (COX)-1 and COX-2
catalyze the formation of the instable PGH2. In a third step,
the production of prostanoids is catalyzed by several terminal
prostanoid synthases. Prostaglandin E2 synthases (PGES) cata-
lyzetheconversionofPGH2toPGE2(Figure1).
1Threeisoforms
of PGES have been described: the two membrane-bound forms
mPGES-1andmPGES-2,aswell asthecytosolicPGES (cPGES).
The latter two are constitutively expressed. cPGES uses PGH2
produced by the constitutively expressed COX-1, mPGES-2 can
use PGH2 produced by both COX isoforms, COX-1, or the
inducible COX-2. mPGES-1, which is also an inducible enzyme,
isprimarilycoupledtoCOX-2.TheexpressionofbothCOX-2and
mPGES-1 is increased in response to pro-inﬂammatory stimuli.
Studies indicate key roles of mPGES-1 in a number of disease
conditions such as inﬂammation, arthritis, fever, pain, anorexia,
atherosclerosis, stroke, and cancer.
2
Speciﬁc inhibition of mPGES-1 is expected to interfere with
inﬂammation-induced PGE2 formation whereas physiological
PGE2 as well as other COX-derived prostanoids are not
suppressed.
3,4 The idea is that mPGES-1 inhibitors may not lead
to side eﬀects commonly associated with nonsteroidal anti-
inﬂammatory drugs (NSAIDs) and coxibs. Thus, there is an
increasing interest in this novel therapeutic strategy as an
alternative to presently available anti-inﬂammatory drugs. How-
ever, to date, no pharmacological evidence for this theory in
humans has been reported. Although a few inhibitors are currently
in clinical trials, no mPGES-1 inhibitor is available on the market.
Several inhibitors of mPGES-1 have been identiﬁed in vitro,
including PG analogues and fatty acids.
5,6 Highly potent mPGES-
1 inhibitors include predominantly acidic indole derivatives
4,7,8
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ABSTRACT:MicrosomalprostaglandinE2synthase-1(mPGES-
1) catalyzes prostaglandin E2 formation and is considered as a
potential anti-inﬂammatory pharmacological target. To identify
novel chemical scaﬀolds active on this enzyme, two pharmaco-
phore models for acidic mPGES-1 inhibitors were developed
and theoretically validated using information on mPGES-1
inhibitors from literature. The models were used to screen
chemicaldatabasessuppliedfromthe National Cancer Institute
(NCI) and the Specs. Out of 29 compounds selected for
biological evaluation, nine chemically diverse compounds caused concentration-dependent inhibition of mPGES-1 activity in a
cell-free assay with IC50 values between 0.4 and 7.9 μM, respectively. Further pharmacological characterization revealed that also
5-lipoxygenase(5-LO)wasinhibitedbymostoftheseactivecompoundsincell-freeandcell-basedassayswithIC50valuesinthelow
micromolar range. Together, nine novel chemical scaﬀolds inhibiting mPGES-1 are presented that may possess anti-inﬂammatory
properties based on the interference with eicosanoid biosynthesis.3164 dx.doi.org/10.1021/jm101309g |J. Med. Chem. 2011, 54, 3163–3174
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andnonacidicphenanthrenederivatives.
4,9Thehighlypotentindole
compound 1 showed an IC50 value of 3 nM,
7 whereas an IC50 of
0.7nMwasdetermined for the phenanthrene imidazole compound
2.
4Compound3,alsoknownasMK-886(IC50=2.4μM
10),which
was one of the ﬁrst mPGES-1 inhibitors, is commonly used as
reference inhibitor in mPGES-1 assays (Chart 1).
San Juan and Cho
11 as well as AbdulHameed et al.
8 described
theories on mPGES-1 ligand binding in their 3D-quantitative
structure activity relationship (QSAR) studies on mPGES-1
inhibitors. Structures that were very similar to our training set
compounds 4 and 5 were used in these studies. The overall
binding site architecture was described similarly in both publica-
tions;aminoacidnumberingwasnotconsistentamongthesetwo
studies.Accordingtotheirresults,theinteractionsiteofmPGES-1
consists of a so-called cationic site and an anionic site. In the
cationic site of the receptor, there is a large hydrophobic region
whichmaybeimportantfortheselectivityofligandsformPGES-1.
Important amino acids therein might be Val residues. Ser, Thr,
and/or Ala residues might form hydrogen bonds with suitable
substituents of the ligand. In the anionic site of the receptor, a
basic Arg, which was reported to have catalytic function,
12 is
expected to interact with the ligand, ideally an acidic group.
The aimof our study was toﬁnd novelinhibitorsof mPGES-1
using pharmacophore modeling and virtual screening. Although
Jegersch€ old et al.
13 described the X-ray crystal structure of
mPGES-1, a ligand-based modeling approach was applied. As
already pointed out by R€ orsch and co-workers in a recent virtual
screening report on nonacidic mPGES-1 inhibitors,
14 the pub-
lished X-ray structure represents a closed conformation of the
binding site, which makes a structure-based virtual screening
Figure1. Prostaglandinbiosyntheticpathway.
1PLA2,phospholipaseA2;COX,cyclooxygenase;PG,prostaglandin;PGDS,prostaglandinD2synthase;
PGES, prostaglandin E2 synthase; PGFS, prostaglandin F2R synthase; PGIS, prostaglandin I2 synthase; TXS, thromboxane A2 synthase; TXA2,
thromboxane A2.
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approach rather diﬃcult. In contrast to the work of R€ orsch et al.,
our study presents a ligand-based pharmacophore modeling and
virtual screening strategy leading to novel acidic mPGES-1
inhibitors.
’RESULTS AND DISCUSSION
A workﬂow overview of this study including pharmacophore
modeling, selection of compounds, and biological testing is
provided in Scheme 1.
Pharmacophore Model Generation and Theoretical Vali-
dation.Aligand-basedpharmacophoremodelforacidicmPGES-1
inhibitors was developed using the HipHopRefine algorithm of
Catalyst 4.11. Model generation was based on the structural
information of six acidic indole derivatives described in literature
as inhibitors of mPGES-1.
4,7 Although these compounds were
all members of the same chemical class, they were selected for
model building due to their potent mPGES-1 inhibition
(compounds 4 and 5). Literature data on other acidic inhibitors
did not report such highly active compounds.
15 Therefore, this
was the most promising starting point to generate a high quality
pharmacophore model. Although the training compounds were
so similar, novel active inhibitors were expected from pharma-
cophore-based searches due to the well-known scaffold hopping
potentialofpharmacophoremodels.
16Thetrainingsetstructures
were divided into three groups: Highly active compounds with
IC50 values in the low nanomolar range (4 and 5)w e r eg i v e n
priority one. The algorithm calculated numerous pharmacophore
models based on the 3D alignment of these two structures.
Compounds 6 and 7 were given priority two; hence, pharmaco-
phoremodelsthatdidnotrecognize themwerediscarded,which
resulted in a smaller model collection. Two structures showing
activityinamicromolarrange (8and9;priority three)(Table1)
were used to identify the most valuable pharmacophore model.
In this last step, the algorithm deleted models that recognized
these structures with a high fit value. The best pharmacophore
model consisted of six features: four hydrophobic (H) features,
one aromatic ring (RA), and one negatively ionizable (NI)
feature. This model correctly recognized compounds 4 7, and
discarded 8 and 9. To include additional information on com-
poundsizeandshape,astericconstrictionwasadded:compound4
wasfittedintothemodel,convertedintoashapequery,andmerged
with the chemical features of the initial pharmacophore (Figure 2).
To validate the ability of the pharmacophore model to dif-
ferentiate between biologically active and inactive molecules, the
model was screened against an mPGES-1 inhibitor test set. This
test set contained 10 mPGES-1 inhibitors that were not part of
the training set and have been obtained from diﬀerent literature
sources (Chart 2).
4,7,17 19
To this test set, 72 compounds that have been biologically
tested but did not inhibit mPGES-1 were added (Supporting
Information Chart S1).
4,7,14,17 21 The pharmacophore model
for mPGES-1 inhibitors recognized 2 out of 10 active test set
structures (20%),
4,7,15 both indole derivatives (Table 2).
None of the 72 conﬁrmed inactive molecules matched the
model. The enrichment factor for this validation result was 8.2,
Scheme 1. Study Design Providing (A) Pharmacophore Modeling, (B) Selection of Virtual Hit (VH) Compounds, and (C)
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which indicated an excellent discriminatory power and usability
for virtual screening.
However, the retrieval of only two active molecules showed
the models restriction to certain chemical scaﬀolds. Thus, a
second model was developed with the aim of broader focus on
novel scaﬀolds. Therefore, the test set compounds from Chart 2
were added to the training compounds and ﬁtted into the initial
model, allowing one feature not to be mapped. According to the
intention of this study to ﬁnd new acidic inhibitors of mPGES-1,
the NIfeature was keptmandatory for ﬁtting. The shape was not
modiﬁed either because the hit list should not comprise struc-
tures of very high molecular weight. Thereby, all 14 compounds
from Table 1 and Chart 2 with IC50 values <5 μM (the two least
active compounds 9 and 10 were not found) were retrieved
bythemodel,whichmeansthattheymatched theNIfeature,the
shape, and four out of the ﬁve H/RA features. An analysis
of mapping features did not give a clear preference of some
H features or the RA feature over others. Accordingly, it could
notbeﬁguredoutwhichoftheremainingfeatures(theHonesor
the RA) are most important for ligand activity. Thus, a partial
query model was selected, allowing for missing any one of the
HortheRAfeatures.Thepartialquerymodelretrieved12outof
72 inactive compounds(S16, S20, S30, S36,S40, S45, S48, S49,
S51, S53, S59, S61). This indicated that the partial query model
withagoodretrievalofactivecompounds(activeshitrate87.5%)
and suﬃcient selectivity against inactive ones (inactives hit rate:
16.7%) has a high probability to identify structurally diverse
scaﬀolds. Because our intention was not only to identify novel
analogues of known mPGES-1 inhibitors but also to discover
new classes of chemical scaﬀolds, we decided to use both the
selectiveoriginalmodelandthepromiscuouspartialquerymodel
for virtual screening.
Selection of Compounds for Biological Testing. The phar-
macophore models were experimentally validated using substances
provided by the National Cancer Institute (NCI), USA, and Specs,
TheNetherlands.First,theNCIdatabase(version2003,comprising
247041compounds)wasscreenedwiththerestrictivemodel,which
led to a hit list of 81 compounds mapping all six pharmacophore
model features. Because of the low number of VH, the Specs
database (version 09/2010, comprising 200015 compounds) was
screened, leading to 70 VH. These 151 VH were clustered by
structural diversity and inspected for reactive and nondrug-like
Table 1. Training Set Compounds Used for Pharmacophore Model Generation3167 dx.doi.org/10.1021/jm101309g |J. Med. Chem. 2011, 54, 3163–3174
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groups. In total, 20 chemically diverse compounds were selected
for biological testing (compounds S73 S82 from NCI, Support-
ingInformationChartS2,compounds20 25andS83 S86from
Specs, Supporting Information Chart S3).
1,337 VH were retrieved from screening of the NCI database
with the partial query model. They were submitted to the same
selection process as described above, and 14 chemically diverse
structureswereselectedforbiologicaltesting(compoundsS87 
S97 and 26 28, Supporting Information Chart S4).
Results of Experimental Evaluation. Five out of the 34 ac-
quired compounds (S76, S81, S89, S90,a n dS97)c o u l dn o tb e
tested due to solubility problems in dimethyl sulfoxide (DMSO),
ethanol, and water. The other 29 compounds were investigated in a
cell-free mPGES-1 assay which is based on the mPGES-1-mediated
enzymatic conversion of PGH2 as substrate to PGE2;t h el a t t e rw a s
analyzed by high performance liquid chromatography (HPLC) as
described below. In a first screening round, all compounds (sol-
ubilized in DMSO) were tested at a concentration of 10 μM. The
mPGES-1 inhibitor 3
10 was used as reference control, and DMSO
(0.3%, v/v) was used as vehicle control. As shown in Figure 3A, nine
compounds (i.e., 20 28, Chart 3) showed significant inhibition of
mPGES-1 activity. The purity of these nine active compounds was
determined using HPLC coupled to mass spectrometry (HPLC-
MS). All nine substances showed g95% purity.
A more detailed analysis of the nine active compounds in
concentration response studies revealed a potent, concentra-
tion-dependent inhibition of mPGES-1 activity by 26 and 28
with IC50 values of 0.4 and 0.5 μM, respectively. Compounds
20 25and27werelessactiveinthistestsystemwithIC50values
in the range of 2.3 7.9 μM, respectively (Figure 3B, Table 3).
Compounds 20 25 were found by the restrictive model and
26 28 by the partial query model, respectively.
BothpharmacophoremodelsforacidicinhibitorsofmPGES-1
were therefore successfully experimentally validated with a total
hitrateof31%activecompoundsinthevirtualscreeninghitlists.
The structures of the nine identiﬁed mPGES-1 inhibitors are
chemicallydiverse,whichprovesthatthepharmacophoremodels
are applicable to scaﬀold hopping. These results conﬁrm the
predictive power of the models, which will be used in further
virtual screening experiments.
Three identiﬁed active compounds omitted one feature of the
restrictivepharmacophore model foracidicmPGES-1 inhibitors,
which suggests that they do not cover the whole mPGES-1
binding site. Thus, compounds 26, 27, and 28 omitted the H
featureH6,theRA,andtheHfeatureH4,respectively(Figure4).
Neglecting such diverse features does not indicate which one of
thesemightbeoflessimportanceforthebioactivity.Chenetal.
22
suggested in their study on 3D-QSAR pharmacophore mapping
of35nonacidicmPGES-1inhibitorsthatahydrogenbonddonor
and three H features are crucial for ligand activity. Some of the
generated QSAR models also included RA features, occasionally
replacing an H feature. In our model, a RA feature overlapped
with an H feature, thereby supporting the results from Chen
et al.
22 In the absence of a cocrystal structure with an inhibitor,
the actual impact of hydrophobic or aromatic functionality is
hard to predict at this step.
Docking Studies for mPGES-1 Inhibitors. As a comparison
of the ligand-based pharmacophore models with information
from the X-ray crystal structure, induced fitdocking experiments
were performed with compounds from literature as well as with
the most active, newly identified inhibitor 26. Docking of
compound 4 and the analysis of predicted protein ligand
interactions confirmed the locations of NI and H chemical
features contained in the pharmacophore models. For the RA
feature, no corresponding protein ligand interaction could be
observed (Figure 5). Docking of compound 26 resulted in a
binding mode that is shown in Figure 6. More detailed informa-
tion on the molecular docking experiments performed in this
study is given in the Supporting Information.
Previous studies with other mPGES-1 inhibitors showed that
some of them also interfere with the activity of 5-lipoxygenase
(5-LO). Such dual mPGES-1/5-LO inhibitors are, for instance,
licofelone
23,24 and pirinixic acid derivatives.
17 Thus, the newly
identiﬁed mPGES-1 inhibitors were further investigated con-
cerning their potential to interfere with 5-LO activity. 5-LO
catalyzes the initial steps in the biosynthesis of leukotrienes
(LTs), which are further central mediators in inﬂammatory
reactions, as reviewed by Peters-Golden and Henderson.
25
Inhibition of the activity of human recombinant 5-LO in a cell-
freeassaybycompounds20 28wasdetermined.Compound20
was inactive in this test system, but the remaining eight com-
pounds suppressed 5-LO activity in a concentration-dependent
manner. Compound 21 even showed to be highly active with an
IC50 = 0.8 μM, comparable to the control 5-LO inhibitor S98
(BWA4C, Supporting Information Chart S5).
Toconﬁrmthebioactivityofthecompoundson5-LO,human
polymorphonuclear leukocytes (PMNL) expressing 5-LO were
used to investigate 5-LO inhibition in a cell-based test system.
Therein, compounds 20 23 and 25 28 (at a concentration of
10μM,respectively)provedtoinhibit5-LOwithresidualactivity
below 50% of control, whereas compound 24 was hardly active
(Table3).Furtherexperimentsatdiﬀerent concentrationsofthe
inhibitors were carriedout inorder todeterminethe IC50 values.
5-LO product synthesis was reduced concentration-dependently
byallnineinhibitors(Figure7).Ofinterest,compound25wasthe
most potent inhibitor in this test system with an IC50 =0 . 8 5μM.
An overview of the pharmacological results determined within
this study is provided in Table 3.
Finally, the ability of the most potent novel mPGES-1
inhibitors (i.e., compounds 26 and 28) to induce cytotoxicity
wasdetermined.Neithercompound26norcompound28(10μM,
each) reduced the viability of human lung epithelial carcinoma
Figure 2. (A) Pharmacophore model for acidic mPGES-1 inhibitors
consisting of one aromatic ring (RA, brown), one negatively ionizable
group (NI, dark blue), four hydrophobic features (H3 6, cyan), and a
shape of the most potent inhibitor from the training set (compound 4).
(B) Compound 4 mapped to the pharmacophore model.3168 dx.doi.org/10.1021/jm101309g |J. Med. Chem. 2011, 54, 3163–3174
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A549 cells or leukemic Jurkat A3 T lymphocytes (Supporting
Information Figure S1).
’CONCLUSIONS
Withinthisstudy,pharmacophoremodelingandvirtualscreen-
ing led to the identiﬁcation of novel dual inhibitors of mPGES-1
and 5-LO activity. Therefore, our novel pharmacophore models
are valuable tools for selecting test compounds from various
databases. The nine identiﬁed active compounds 20 28 were
not only strong inhibitors of mPGES-1 in cell-free assays but
were also able to inhibit 5-LO in cell-free assays and/or in intact
cells. On the one hand, selective inhibitors are desired to learn
more about the target and its binding site. On the other hand,
simultaneous inhibition of several physiologically related targets
supports the multitarget idea.
26 The interference with several
anti-inﬂammatory targets from the arachidonic acid cascade
should provide beneﬁts in pharmacotherapy in terms of syner-
gistic therapeutic eﬀects as well as reduction of the incidence of
typicalNSAID-relatedsideeﬀects.Futurestudieswilladdressthe
investigation of the overall pharmacological proﬁle of com-
pounds 20 28 in more detail and will aim to assess their anti-
inﬂammatory activity in vivo.
’EXPERIMENTAL SECTION
Hardware and Software Specifications. Molecular modeling
studieswerecarriedoutonapersonalcomputerrunningFedora8Linux.
Pharmacophore modeling and virtual screening experiments were
performed using Catalyst 4.11 software (Accelrys Inc., San Diego, CA,
USA). Structural clustering of VH compounds was calculated using
PipelinePilot version 7.5 (Accelrys Inc., San Diego, CA, USA).
Chart 2. Ten Active mPGES-1 Inhibitors from the Literature, Which Were Used as Test Set Compounds3169 dx.doi.org/10.1021/jm101309g |J. Med. Chem. 2011, 54, 3163–3174
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DataPreparation.Allcompoundsfromthetrainingandtestsetsas
well as the NCI and the Specs compound collection underwent 3D
structure generation, minimization, and conformational analysis before
the pharmacophore model development and virtual screening. The
ligands from the training and the active compounds from the test set
were built using the View Compound Workbench module of Catalyst
4.11. Compounds were optimized in 3D geometry and energetically
minimized using the CHARMm force field implemented in Catalyst. A
maximumof250conformersperligandwithamaximalenergythreshold
of 20 kcal/mol above the calculated energy minimum was computed
using Catalyst’s BEST conformation generation mode. The NCI
database was downloaded from the NCI download page (dtp.nci.nih.
gov/docs/3d_database/Structural_information/structural_data.html)
andconvertedintoa3DmulticonformationaldatabaseusingthecatDB
module of Catalyst 4.11. For each molecule, a maximum of 100 con-
formers,respectively,wascomputedinFASTmode.TheresultingNCI
database contained 247041 entries.
In a quite similar way, the Specs database was downloaded from the
vendor homepage (www.specs.net). The conformational model for the
database entries was calculated using the catDB module and FAST
mode, with up to 100 conformers per molecule. The resulting 3D
database required for the virtual screening consisted of 200015 entries.
Compilation of Test Set Molecules for Theoretical Model
Validation. Ten mPGES-1 inhibitors were obtained from literature
based on their diversity and potency. In addition, 72 structurally unique
compounds were found in literature that showed no inhibitory activity
formPGES-1inbiologicalassays.Theseconfirmedinactiveswereadded
Table 2. Mapping of Active Literature-Derived Test Set
Compounds into the Restrictive and the Partial Query
Pharmacophore Models
compd
IC50
[μM]
ﬁt value
a restrictive
model
ﬁt value partial
query model
10 5.1 0.00 0.00
11 0.06 1.56 3.53
12 2.6 0.00 1.50
13 0.9 0.00 1.60
14 0.06 0.00 2.32
15 3.9 0.00 1.67
16 0.007 4.06 4.26
17 1.7 0.00 3.23
18 0.07 0.00 2.05
19 1.3 0.00 2.89
aThe ﬁt value is a quantitative metric, that indicates how well the
chemical functions of the ligand geometrically map the features of the
pharmacophore model. The maximum ﬁt value for the reported models
was 6 (each feature had a weight of 1).
Figure 3. Inhibition of mPGES-1 in cell-free assay, given as mean ( SE residual activity in % of uninhibited control (100%, vehicle). (A) Inhibition by
test compounds (10 μM), n =3  10. (B) Concentration-dependent inhibition of mPGES-1 by compounds 20 to 28, n =3  7.3170 dx.doi.org/10.1021/jm101309g |J. Med. Chem. 2011, 54, 3163–3174
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to the mPGES-1 inhibitor test set. Energetically minimized 3D struc-
tures and conformers for the 10 active and 72 inactive molecules of the
test set were generated as mentioned above.
Pharmacophore Model Generation and Theoretical Vali-
dation. For model building and refinement, the HipHop Refine
algorithm of Catalyst 4.11 was employed. This algorithm considers a
maximum of five different chemical feature types. On the basis of an
analysis of the chemical features present in the training set structures,
hydrogen bond acceptor, hydrogen bond donor, H, RA, and NI features
were selected for this study. For the calculation setup, two ligand
properties have to be specified. The principal value indicates the activity
level of the molecule. A high principal value of 2 gives the molecule top
priority and labels it as a reference molecule of which all chemical
features are considered in building the pharmacophore space during
model generation. The principal value of 1 labels a molecule as
moderately active. Conformations ofthismolecule are considered when
placing pharmacophore features. Finally, a principal value of 0 indicates
low or absent activity of this molecule. Those compounds are not
Chart 3. Structures of Compounds 20 28 that Inhibited mPGES-1 in the Cell-Free Assay
Table 3. Bioactivity of Compounds 20 28 in Diﬀerent Assays Determined within This Study
compd
mPGES-1 activity
% of control at 10 μM
mPGES-1 activity
IC50 [μM]
5-LO activity, cell-free
% of control at 10 μM
5-LO activity, cell-free
IC50 [μM]
5-LO activity, intact PMNL
% of control at 10 μM
5-LO activity,
intact PMNL
IC50 [μM]
20 18.3(3.0 2.3 107.9(16.9 >10 10.9( 3.5 4.7
21 15.7(1.8 2.8 6.3( 3.5 0.8 17.4(6.3 5.4
22 43.2( 6.7 7.9 22.3(2.3 5.5 4.3(0.6 2.8
23 25.1(2.3 2.6 40.1(8.2 9.2 49.0(1.1 9.8
24 36.5(4.6 7.7 40.4(9.0 8.0 65.5( 5.7 >10
25 21.6(4.0 3.0 21.1( 3.4 5.2 3.6(1.7 0.85
26 15.2(1.1 0.4 9.5(3.2 2.9 5.9(4.1 2.7
27 35.9(2.1 3.7 37.5 (6.8 5.7 8.2(0.9 4.5
28 17.3( 3.3 0.5 2.6(0.7 1.9 30.7(7.0 2.3
control inhibitors 19.2(3.8(3) 2.2(3) 48.4(4.6(S98,0.3μM) 0.36(S98) 17.9(3.2(S98,0.3μM) 0.11 (S98)3171 dx.doi.org/10.1021/jm101309g |J. Med. Chem. 2011, 54, 3163–3174
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considered for common feature pharmacophore model building. How-
ever, they are considered for placing exclusion volume spheres. The
second ligand property to define is the MaxOmitFeat value. This
parameter specifies how many features are allowed to miss for each
molecule. A MaxOmitFeat value of 0 indicates that all features in the
generated model must map the compound. MaxOmitFeat 1 allows that
allbutoneofthefeaturesinthegeneratedpharmacophoremustmapthe
compound. A MaxOmitFeat value of 2 indicates that no features from
the model need to map the compound. For the calculation of the
mPGES-1 model, compounds 4 and 5 had a principal value of 2 and a
MaxOmitFeat value of 0. Compounds 6 and 7 were assigned principal
and MaxOmitFeat values of 1, while compounds 8 and 9 were given a
principal value of 0 and a MaxOmitFeat value of 2. The shape of
compound 4 was generated by mapping the molecule into the initial
pharmacophoremodelusingtheCompare/FittoolofCatalyst4.11with
0allowedomittedfeatures.Thebestfittingconformation,whichshowed
the maximum possible fit value, was transformed into a shape query and
merged with the chemical features of the initial model.
Virtual screening of the test set was performed using the fast (rigid)
search algorithm of Catalyst 4.11. Fit calculations were computed using
Figure 4. Fitting of the most active mPGES-1 inhibitors 26 (A) and 28 (B) into the mPGES-1 partial query pharmacophore model.
Figure 5. Predicted binding mode of compound 4 to mPGES-1. (A) 2D depiction of all observed protein ligand interactions. (B) Protein ligand
interactions corresponding to the ligand-based pharmacophore features. Chemical interactions are color-coded: hydrophobic, yellow; negative charge,
red. Arg110 and Arg126 from the basic subpocket are shown in ball-and-stick style.
Figure 6. Predicted binding mode of compound 26 to mPGES-1. (A) 2D depiction of all observed protein ligand interactions. (B) Protein ligand
interactions corresponding to the ligand-based pharmacophore features. Chemical interactions are color-coded: hydrophobic, yellow; negative charge,
red. Arg126 from the basic subpocket is shown in ball-and-stick style.3172 dx.doi.org/10.1021/jm101309g |J. Med. Chem. 2011, 54, 3163–3174
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the“bestﬁt”mode,whichallowslimitedconformationalﬂexibilityofthe
ligand while ﬁtting to the pharmacophore model.
Virtual Screening of the NCI and the Specs Databases,
StructuralClustering,andSelectionofTestCompounds.The
NCI and the Specs databases were screened using the same settings as
for the test set compound screening. VH were clustered according to
their structural diversity using Pipeline Pilot. The script converted the
structures intoSciTegic’s ECFPsand determinedthesimilarity between
these fingerprints applying the Tanimoto coefficient. From each cluster,
compounds were mapped to the model for visual inspection.
Test Compounds. Test substances used for the biological inves-
tigation were either purchased from Specs, The Netherlands, or kindly
provided by the Drug Synthesis and Chemistry Branch, Developmental
Therapeutics Program, Division of Cancer Treatment and Diagnosis,
NCI,USA.Thepurityofcompounds20 28,whichinhibitedmPGES-1
formation with an IC50 below 10 μM, was determined by HPLC-MS to
be g95%.
Assay Systems, Materials. Dulbecco’s Modified Eagle Medium
(DMEM)/High Glucose (4.5 g/L) medium, RPMI medium, penicillin,
streptomycin, trypsin/ethylenediaminetetraacetate (EDTA) solution,
N-2-hydroxyethylpiperazine-N0-2-ethanesulfonic acid (HEPES), and
LSM 1077 lymphocyte separation medium were obtained from PAA
(Pasching, Austria). IL-1β was obtained from ReproTech (Hamburg,
Germany). Fetal calf serum (FCS), phenylmethanesulphonyl fluoride
(PMSF),leupeptin,soybeantrypsininhibitor(STI),glutathione(reduced),
compound S98,P G B 1,l y s o z y m e ,C a
2þ-ionophore A23187, arachidonic
acid, thiazolyl blue tetrazolium bromide (MTT), and cycloheximide
were obtained from Sigma-Aldrich (Deisenhofen, Germany). Com-
pound 3 and 11β-PGE2 were obtained from Cayman Chemical (Ann
Arbor, MI). PGH2, adenosine triphosphate (ATP), isopropyl-β-D-1-thioga-
lactopyranoside (IPTG), dextrane, and staurosporine were obtained from
Larodan (Malmoe, Sweden), Roche Diagnostics (Mannheim, Germany),
AppliChem (Darmstadt, Germany), Fluka (Neu-Ulm, Germany), and
Calbiochem (San Diego, CA), respectively. A549 and Jurkat A3 cells
wereprovidedbytheKarolinskaInstitute(Stockholm,Sweden)andDr.
John Blenis (Boston, MA), respectively. Leukocyte concentrates from
human healthy volunteers were provided by the Institute for Clinical
Transfusion Medicine (University Hospital Tuebingen, Germany).
CellCulture. Cellswereculturedintherespectivemediaat37 Cin
a6 %C O 2 incubator. Jurkat A3 cells were grown in RPMI medium
containing heat-inactivated FCS (10%, v/v), HEPES (10 mM), peni-
cillin (100 U/mL), and streptomycin (100 μg/mL) and reseeded with a
density of 2   10
5 cells/mL medium after three days. A549 cells were
growninDMEMHighGlucose(4.5g/mL)mediumsupplementedwith
heat-inactivated FCS (10%, v/v), penicillin (100 U/mL), and strepto-
mycin (100 μg/mL). After three days, confluent cells were detached
using 1  trypsin/EDTA and reseeded with a density of 10
5 cells/mL
medium.
Preparation of Crude mPGES-1 in Microsomes of A549
Cells and Determination of mPGES-1 Enzymatic Activity.
Preparation of A549 cells and determination of mPGES-1 activity was
performedasdescribedpreviously.
24Inbrief,A549cellsweretreatedwith
1ng/mLinterleukin-1βfor48hat37 Can d5 %CO 2.Aftersonification,
the homogenate was subjected to differentialcentrifugationat10000g for
10minand174000gfor1h at4 C.Thepellet(microsomalfraction)was
resuspendedin1mLhomogenizationbuffer(0.1Mpotassiumphosphate
buffer pH7.4, 1 mMPMSF, 60μg/mLSTI,1 μg/mLleupeptin, 2.5 mM
glutathione, and 250 mM sucrose), and the total protein concentration
was determined. Microsomal membranes were diluted in potassium
phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione. Test
compounds or vehicle were added, and after 15 min at 4  C, the reaction
(100 μL total volume) was initiated by addition of PGH2 (20 μM, final
concentration, unless stated otherwise). After 1 min at 4  C, the reaction
was terminatedusing stop solution(100 μL;40 mMFeCl2, 80 mMcitric
acid, and 10 μMo f1 1 β-PGE2 as internal standard). PGE2 was separated
by solid phase extraction and analyzed by RP-HPLC as described.
24
Docking Studies. Docking was performed using the induced fit
docking module available within Maestro (www.schr€ odinger.com). The
X-ray crystal structure of mPGES-1, which does not include a substrate
or inhibitor of the enzyme and is crystallized in a closed conformation,
was derived from the PDB (code 3dww)
13 and preprocessed using the
Protein Preparation Wizard of Maestro software suite. Details on ligand
and protein preparation, setting for induced fit docking, and docking
validation are available as Supporting Information.
Expression and Purification of Human 5-LO from Escher-
ichia coli (E. coli). E. coli MV1190 was transformed with pT3 5-LO
Figure 7. Concentration-dependent inhibition of 5-LO product formation in human PMNL by compounds 20 28, given as mean ( SE residual
activity in % of uninhibited control (100%, vehicle); n =4 .3173 dx.doi.org/10.1021/jm101309g |J. Med. Chem. 2011, 54, 3163–3174
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plasmid expressing human recombinant 5-LO and the protein was ex-
pressed at 27  C as described.
27 Cells were lysed in 50 mM triethanola-
mine/HCl pH 8.0, 5 mM EDTA, STI (60 μg/mL), 1 mM PMSF, and
lysozyme (500 μg/mL), homogenized by sonication (3   15 s), and
centrifuged at 40000g for 20 min at 4  C. The 40000g supernatant (S40)
wasappliedtoanATP-agarosecolumntopartiallypurify5-LOasdescribed
previously.
27 Semipurified 5-LO was immediately used for activity assays.
Determination of 5-LO Activity in Cell-Free Assay. Aliquots
ofsemipurified5-LO(0.5μg)weredilutedwithice-coldPBScontaining
1 mM EDTA, and 1 mM ATP was added; final volume was 1 mL.
Samples were preincubated with the test compounds as indicated. After
10 min at 4  C, samples were prewarmed for 30 s at 37  C, and 2 mM
CaCl2 plus 20 μM AA was added to start 5-LO product formation. The
reaction was stopped after 10 min at 37  C by addition of 1 mL of ice-
cold methanol, and the formed metabolites were analyzed by RP-HPLC
as described.
28 5-LO products include the all-trans isomers of LTB4 and
5(S)-hydro(pero)xy-6-trans-8,11,14-cis-eicosatetraenoic acid.
Isolation of PMNL and Determination of 5-LO Activity in
PMNL. PMNLwerefreshlyisolatedfromleukocyteconcentratesobtained
at the Blood Center of the University Hospital Tuebingen (Germany) as
described.
29Inbrief,venousbloodwastakenfromhealthyadultdonorsthat
did not take any medication for at least 7 days, and leukocyte concentrates
were prepared by centrifugation (4000g,2 0m i n ,2 0 C). PMNL were
immediately isolated from the pellet after centrifugation on Nycoprep
cushions, and hypotonic lysis of erythrocytes was performed. PMNL were
finallyresuspended in PBSpH7.4(PBS) containing 1mg/mLglucoseand
1m MC a C l 2 (PGC buffer) (purity >96 97%).
Freshly isolated PMNL (10
7/mL PGC buﬀer) were preincubated with
the test compounds for 15 min at 37  C, and 5-LO product formation was
started by addition of 2.5 μM ionophore A23187 plus 20 μM AA. After
10minat37 C,thereactionwasstoppedwith1mLofmethanoland30μL
of 1 N HCl, and then 200 ng PGB1 and 500 μL PBS were added. Formed
5-LO metabolites were extracted and analyzed by HPLC as described.
28
5-LO products include LTB4 and its all-trans isomers, and 5(S)-hydro-
(pero)xy-6-trans-8,11,14-cis-eicosatetraenoic acid. Cysteinyl-LTs C4,D 4,an d
E4were not detected, and oxidation products of LTB4were not determined.
Determination of Cell Viability. Cell viability was assessed by
trypan blue staining and light microscopy as well as by MTT assay. For
MTT assay, Jurkat A3 (3   10
5 cells/mL) or A549 cells (4   10
5) were
plated in a 75 cm
3 cell culture flask and incubated at 37  C and 5% CO2
for 72 h. Then, test compounds were added and the incubation was
continued for 24 h before cell viability was determined as described.
30
The cytotoxic compounds cycloheximide (CHX) and staurosporine
(Stauro) were used as controls.
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taglandin E2 synthase-1;mPGES-2, microsomal prostaglandin E2
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